Biocept Enters Clinical Collaboration with Sarah Cannon Research Institute Focused on Screening ER+ Breast Cancer Patients
"The goal of our collaboration with Sarah Cannon is to identify
biomarkers that can be evaluated through a simple blood draw, without
continually performing tissue biopsies on a patient," said
"Breast cancer is the most prevalent cancer in women, and more than
two-thirds of cases express estrogen receptor (ER). It is encouraging to
see targeted therapies for patients with ER+ disease, which include
recently approved drugs as well as newer options currently available in
clinical trials," said
The collaboration is designed to demonstrate the utility of Biocept's liquid biopsy diagnostics to detect biomarker status in cancer patients, and for the assessment of tumor treatment response over time.
About
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to improvement of outcomes,
our impact on diagnostic strategies and planned future offerings, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors as
set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150603005236/en/
Investor Contact:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media